RhumbLine Advisers’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

RhumbLine Advisers’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-24,195	Closed	-$2.36M	–	3180
2015 Q1	$2.36M	Buy	24,195 +4,941	+26%	+$523K	0.01%	1292
2014 Q4	$1.79M	Buy	19,254 +955	+5%	+$75.4K	0.01%	1429
2014 Q3	$1.26M	Sell	18,299 -1,330	-7%	-$95.2K	﹤0.01%	1609
2014 Q2	$2.06M	Buy	19,629 +2,532	+15%	+$215K	0.01%	1353
2014 Q1	$1.42M	Buy	17,097 +80	+0.5%	+$7.4K	﹤0.01%	1571
2013 Q4	$1.1M	Buy	17,017 +1,570	+10%	+$93.2K	﹤0.01%	1748
2013 Q3	$978K	Sell	15,447 -43	-0.3%	-$2.12K	﹤0.01%	1796
2013 Q2	$651K	Buy	+15,490	New	+$706K	﹤0.01%	2067

RhumbLine Advisers's GEVA Position: Q2 2015 in Review

RhumbLine Advisers sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 24,195 shares — an estimated $2.36M sold.

RhumbLine Advisers first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $2.36M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

RhumbLine Advisers reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
RhumbLine Advisers sold 24,195 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $2.36M.
RhumbLine Advisers first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
RhumbLine Advisers's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.36M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on RhumbLine Advisers's 13F filing for Q2 2015, filed 4 Aug 2015.